Small molecule inhibitors of NMPRTase with antineoplastic and antiangiogenic activities
- IP Title
- SMALL MOLECULE INHIBITORS OF NICOTINAMIDE PHOSPHORIBOSYLTRANSFERASE (NAMPT)
- Detailed Technology Description
- None
- Application Date
- May 30, 2014
- Application No.
- 9,382,267
- Others
-
- *Abstract
-
The molecule NAD+ is extensively utilized in cellular processes including cell signaling and respiration. The drug AP0866, a potent inhibitor of Nampt, the first and rate limiting enzyme of the mammalian NAD+ recycling pathway, is currently being tested in several Phase I and Phase I/II clinical trials against several forms of cancer. In the present invention, we have developed a new class of Nampt inhibitors. The concentration dependent activities of these agents have been tested in-vitro and directly compared with those of AP0866 against six human tumor cell lines including: breast, colon, glioma, prostate, pancreatic and lung cancer. Several of these agents demonstrate significantly higher activity than AP0866 in vitro, exhibiting significantly lower IC50 values, as well as higher cancer cell anti-proliferative effects.POTENTIAL AREAS OF APPLICATION:• Anti-cancer therapy, diabetes, arthritis MAIN ADVANTAGES OF INVENTION: • High potency against tumor cells• Unique composition of matterSTAGE OF DEVELOPMENT:• Preclinical PATENT STATUS:• Patent application in preparation CONTACT INFO:Paul Hippenmeyer, Sr. Licensing & Business Development AssociateOffice of Technology Management and Industry Relations Email: hippenmeyerp@missouri.edu Phone: 573-882-0470
- *IP Issue Date
- Jul 5, 2016
- *IP Publication Date
- Nov 12, 2015
- *Principal Investigator
-
Name: Mark Lee, Assistant Professor of Radiology
Department:
Name: Yulia Sevryugina, Assistant Professor of Inorganic Chemistry
Department:
- Country/Region
- USA
For more information, please click Here
